MANKIND - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.0
| Stock Code | MANKIND | Market Cap | 86,401 Cr. | Current Price | 2,094 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 51.9 | Book Value | 376 ₹ | Dividend Yield | 0.05 % | ROCE | 15.0 % |
| ROE | 13.9 % | Face Value | 1.00 ₹ | DMA 50 | 2,199 ₹ | DMA 200 | 2,344 ₹ |
| Chg in FII Hold | -1.49 % | Chg in DII Hold | 1.35 % | PAT Qtr | 459 Cr. | PAT Prev Qtr | 413 Cr. |
| RSI | 41.5 | MACD | -28.5 | Volume | 3,63,359 | Avg Vol 1Wk | 3,94,579 |
| Low price | 2,059 ₹ | High price | 2,727 ₹ | PEG Ratio | 6.17 | Debt to equity | 0.47 |
| 52w Index | 5.17 % | Qtr Profit Var | -25.2 % | EPS | 40.4 ₹ | Industry PE | 29.0 |
📊 Chart Patterns & Trend: Mankind Pharma is trading at 2,094 ₹, below its 50 DMA (2,199 ₹) and 200 DMA (2,344 ₹). This indicates a bearish consolidation with downward bias. The stock is near its 52-week low (2,059 ₹), reflecting weak sentiment and selling pressure.
📈 RSI: At 41.5, RSI is neutral-to-weak, suggesting limited momentum and no strong rebound signals.
📉 MACD: Negative at -28.5, confirming bearish momentum and lack of bullish crossover signals.
📊 Bollinger Bands: Price is near the lower band, indicating oversold conditions and possible mean reversion.
📊 Volume Trends: Current volume (3,63,359) is slightly lower than average weekly volume (3,94,579), showing weak participation and lack of conviction in recent moves.
🎯 Entry Zone: 2,060–2,100 ₹ (near support and oversold RSI).
🎯 Exit Zone: 2,200–2,250 ₹ (near 50 DMA resistance).
Positive
- Market cap of 86,401 Cr. reflects strong presence in pharma sector.
- Quarterly PAT improved to 459 Cr. from 413 Cr., showing sequential growth.
- DII holdings increased by 1.35%, indicating domestic institutional confidence.
- EPS at 40.4 ₹ supports earnings visibility.
- ROCE (15.0%) and ROE (13.9%) highlight decent capital efficiency.
Limitation
- Stock trading below both 50 DMA and 200 DMA, showing weak momentum.
- High P/E of 51.9 compared to industry PE of 29.0, making valuation expensive.
- Dividend yield is negligible at 0.05%.
- PEG ratio of 6.17 indicates poor earnings growth relative to valuation.
- Volume participation is weak, reducing conviction in price action.
Company Negative News
- Quarterly profit variance of -25.2% highlights declining profitability.
- FII holdings decreased (-1.49%), showing reduced foreign investor confidence.
- Stock trading near 52-week low, reflecting weak sentiment.
Company Positive News
- Sequential PAT growth (459 Cr. vs 413 Cr.) indicates operational improvement.
- DII stake increase reflects domestic investor confidence.
- EPS growth supports long-term earnings visibility.
Industry
- Pharma sector trading at industry PE of 29.0, highlighting Mankind Pharma’s overvaluation.
- Sector outlook remains positive with defensive demand and global healthcare expansion.
Conclusion
⚖️ Mankind Pharma is in a bearish consolidation phase with weak RSI and negative MACD. Entry near 2,060–2,100 ₹ offers margin of safety, while exits around 2,200–2,250 ₹ provide profit-taking opportunities. Long-term investors should be cautious due to high valuations and modest ROE/ROCE, while short-term traders may exploit oversold conditions for swing trades.
Selva, this is workflow-ready. Would you like me to also prepare a standardized HTML template with placeholders for peer benchmarking overlays and sector scans, so you can plug multiple stocks seamlessly into your automation system?